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a b s t r a c t
Background: Few data are available about neointimal tissue characteristics after drug-eluting stent (DES)
implantation in patients with decreased renal function. We used virtual histology-intravascular ultra-
sound (VH-IVUS) to assess the neointimal tissue characteristics according to the baseline renal function.
Methods: We compared neointimal tissue components between patients with chronic kidney disease
(CKD) [n=19, estimated creatinine clearance (CrCl) <60mL/min] and those without CKD (n=229). The
region of interest was placed between the luminal border and the inner border of the stent struts and
tissue components were reported as percentages of neointimal volume.
Results: Mean follow-up durations between DES implantation and follow-up VH-IVUS study were
12.0±4.1 months in the CKD group and 11.4±5.6 months in the non-CKD group (p=0.519). At follow-
up, neointima volumewas signiﬁcantly greater (72±47mm3 vs. 47±26mm3, p<0.001) and %neointima
necrotic core (NC) volume was signiﬁcantly greater (25.0±11.4% vs. 17.9±10.2%, p=0.012) in the CKD
group compared with the non-CKD group. There was negative correlation between CrCl and neointima
volume(r=−0.250,p<0.001), however, therewasnosigniﬁcant correlationbetweenCrCl and%neointima
NC volume (r=−0.034, p=0.591). The only independent predictor of follow-up %neointima NC volume
≥10% was neointima volume (odds ratio 1.025, 95% conﬁdence interval 1.013–1.036, p<0.001).
Conclusions:Renal functionwasassociatedwith in-stentneointimalgrowth, but itwasnotassociatedwith
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in patients who underwe
ntroduction
Cardiovascular disease represents the most important cause of
eath among patients with renal dysfunction [1]. Previous studies
onsistently demonstrated an independent association between
ecreased renal functionandcardiovascular events [1–11]. Patients
ith chronic kidney disease (CKD) had more mortality, myocardialnfarction, repeat revascularization, and bleeding complications
fter percutaneous coronary intervention (PCI) compared with
hose with patients with normal renal function. It has been
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suggested that renal insufﬁciency may predict cardiovascular
events due to an association with more severe coronary artery
disease.
However, few data are available about neointimal tissue char-
acteristics according to the renal function after drug-eluting stent
(DES) implantation. Therefore, thepurposeof thepresent studywas
to attempt to assess the neointimal tissue components between
patients with CKD and those without CKD using virtual histology-
intravascular ultrasound (VH-IVUS).
MethodsPatient population
A total of 248 consecutive patients who underwent gray-scale
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38 lesions, sirolimus-eluting stents in 32 lesions, zotarolimus-
luting stents in 42 lesions, and everolimus-eluting stents in 36
esions) and at follow-up between May 2006 and January 2010
ere identiﬁed from Chonnam National University Hospital VH-
VUS registry database. Follow-up coronary angiogram and IVUS
xaminations were performed in patients with chest pain or pos-
tive non-invasive stress test as well as asymptomatic patients for
outine follow-up. A representative case is shown in Fig. 1.
We compared neointimal tissue components between
atients with CKD [n=19, estimated creatinine clearance
CrCl) <60mL/min] and those without CKD (n=229). Esti-
ated CrCl was calculated applying the Cockcroft–Gault
ormula [12] using the baseline serum creatinine:
rCl = [(140− age)×weight/serum creatinine×72], with female
ender adjustment (CrClfemale = CrCl×0.85).
ig. 1. Theexampleofneointimal tissue components afterdrug-eluting stent implantation
learance 12mL/min). (A) Post-stenting coronary angiogram, (B) post-stenting virtual his
D) 12-month follow-up virtual histology intravascular ultrasound [neointima area: 5.8miology 64 (2014) 98–104 99
The presence of stable angina was determined according to
the Canadian Cardiovascular Society classiﬁcation. The presence of
unstable angina was determined by chest pain within the preced-
ing 72h with or without ST–T-wave changes or positive cardiac
biochemical markers (creatine kinase-myocardial band or cardiac
speciﬁc troponin I). The presence of ST-segment elevation myocar-
dial infarctionwasdeterminedby>30minof continuous chestpain,
a new ST-segment elevation ≥2mm on at least 2 contiguous elec-
trocardiographic leads, and creatine kinase-MB or cardiac-speciﬁc
troponin I > 2 timesnormal. Thepresenceof non-ST-segment eleva-
tionmyocardial infarctionwasdiagnosedbychestpainandpositive
cardiac biochemical markers (creatine kinase-myocardial band or
cardiac-speciﬁc troponin I) without new ST-segment elevation.
The protocol was approved by the institutional review board.
Hospital records of all patients were reviewed to obtain clinical
at one-year follow-up inapatientwith chronic kidneydisease (estimatedcreatinine
tology intravascular ultrasound, (C) 12-month follow-up coronary angiogram, and


























































Baseline gray-scale and VH-IVUS results are summarized in
Table 3. There were no signiﬁcant differences in volumetric gray-








Age (years) 69.7±7.6 60.4±10.3 <0.001
Male gender 16 (84.2%) 161 (70.3%) 0.198
Clinical presentation 0.192
Stable angina pectoris 6 (31.6%) 47 (20.5%)
Unstable angina pectoris 6 (31.6%) 116 (50.7%)
NSTEMI 5 (26.3%) 28 (12.2%)
STEMI 2 (10.5%) 38 (16.6%)
Diabetes mellitus 13 (68.4%) 69 (30.1%) 0.001
Hypertension 9 (47.4%) 118 (51.5%) 0.727
Smoking 4 (21.1%) 72 (31.4%) 0.581
Prior MI 1 (5.3%) 8 (3.5%) 0.692
Previous PCI 3 (15.8%) 9 (3.9%) 0.021
Ejection fraction (%) 59.0±11.5 63.2±8.9 0.052
White blood cells (103/mm3) 8.6±4.6 8.0±3.0 0.422
Hemoglobin (g/dl) 12.2±1.4 13.7±1.5 <0.001
Platelet count (103/mm3) 194±73 236±73 0.017
Glucose (mg/dl) 170±56 136±38 0.019
Creatinine (mg/dl) 2.2±1.8 0.8±0.2 <0.001
Fibrinogen (mg/dl) 262±86 276±69 0.419
hs-CRP (mg/dl) 0.59±0.91 0.56±1.84 0.946
NT-pro-BNP (ng/mL) 1501±3115 326±586 <0.001
Total cholesterol (mg/dl) 179±56 186±38 0.573
Triglyceride (mg/dl) 114±73 115±70 0.947
LDL cholesterol (mg/dl) 115±49 119±34 0.679
HDL cholesterol (mg/dl) 46±14 49±12 0.406
Apolipoprotein A1 (mg/dl) 118±24 129±20 0.023
Apolipoprotein B (mg/dl) 88±30 94±24 0.372
Lipoprotien (a) (mg/dl) 22±17 30±31 0.22600 Y.J. Hong et al. / Journal o
emographics and medical history. Written informed consent was
btained from all patients before cardiac catheterization.
aboratory analysis
Peripheral blood samples were obtained before coronary
ngiography using direct venipuncture. The blood samples were
entrifuged, and serum was removed and stored at −70 ◦C
ntil the assay could be performed. The serum levels of total
holesterol, triglyceride, low-density lipoprotein cholesterol, and
igh-density lipoprotein cholesterol were measured by standard
nzymatic methods. High-sensitivity C-reactive protein was ana-
yzed turbidimetrically with sheep antibodies against human
-reactive protein; this has been validated against the Dade-
ehring method [13]. Serum N-terminal pro-B-type natriuretic
eptide was measured using an electrochemiluminescence sand-
ich immunoassay method with an Elecsys 2010 analyzer (Roche
iagnostics, Mannheim, Germany).
VUS imaging and analysis
All gray-scale and VH-IVUS examinations were performed
fter intracoronary administration of 300g nitroglycerin using a
0-MHz, 2.9F IVUS imaging catheter (Eagle Eye, VolcanoCorp., Ran-
ho Cordova, CA, USA) with automated pullback with a speed of
.5mm/s. All IVUS studies were archived onto CD-ROM and sent
o the IVUS core laboratory for ofﬂine quantitative and qualitative
nalyses by individuals blinded to treatment allocation. Gray-scale
nd VH-IVUS data were analyzed by 2 independent observers
H.Y.J. and C.Y.H.). The levels of reproducibility for the ﬁbrous (FT),
bro-fatty (FF), dense calcium (DC), and necrotic core (NC) vol-
me measurements using the Spearman rank-order correlation
oefﬁcients were 0.93, 0.94, 0.93, and 0.93, respectively.
Quantitative volumetric gray-scale and VH-IVUS analyses were
erformedacross theentire lesionsegment. Conventionalquantita-
ive volumetric gray-scale IVUS analysis was performed according
o the American College of Cardiology Clinical Expert Consensus
ocument on Standards for Acquisition, Measurement and Repor-
ing of Intravascular Ultrasound Studies [14]. Quantitative analysis
ncluded measurement every 1mm of the vessel, stent, and lumen
ross-sectional areas (CSAs). The region of interest was placed
etween the luminal border and the inner border of the stent struts.
eointimal hyperplasia CSA was calculated as stent minus lumen
SA at follow-up. Once a complete set of CSA measurements was
btained, vessel, stent, lumen, and neointima volumes were calcu-
ated with Simpson’s rule. %Volume obstruction was calculated as
eointima volume divided by stent volume. VH-IVUS analysis clas-
iﬁed the color-coded tissue into four major components: green
FT); yellow-green (FF); white (DC); and red (NC) [14–18]. Baseline
laque components were reported as absolute amounts and as a
ercentage of plaque volume. And, plaque components of neointi-
al tissue were obtained by measuring areas between lumen and
ust inside the stent strut to reduce the stent strut artifact (Fig. 1D)
s absolute amounts and as a percentage of plaque volume.
tatistical analysis
The Statistical Package for Social Sciences (SPSS) for Windows,
ersion 15.0 (Chicago, IL, USA) was used for all analyses. Continu-
us variables are presented as the mean value±1SD; comparisons
ere conducted by Student’s t-test or nonparametric Wilcoxon
est if normality assumption was violated. Discrete variables are
resented as percentages and relative frequencies; comparisons
ere conducted by chi-square statistics or Fisher’s exact test as
ppropriate. Pearson’s correlation coefﬁcient was used to evalu-
te the associations between CrCl and IVUS parameters. Usually,iology 64 (2014) 98–104
we deﬁne thin-cap ﬁbroatheroma in de novo atherosclerosis as a
NC≥10% of plaque area in at least 3 consecutive frames without
overlying ﬁbrous tissue in the presence of ≥40% plaque burden
[16]. Therefore, using the cut-off levels of 10% for greater NC
amounts, we performed multivariate analysis to identify the inde-
pendent predictors of follow-up %neointima NC volume ≥10% and
all variables with p-value <0.10 in univariate analysis were tested.
A p-value <0.05 was considered statistically signiﬁcant.
Results
Baseline characteristics
The baseline characteristics are summarized in Table 1. The
CKD group was signiﬁcantly older and included more diabetics
compared with the non-CKD group. The CKD group had lower
hemoglobin, lower platelet count, higher glucose, and higher
N-terminal pro-B type natriuretic peptide compared with the
non-CKD group.
Coronary angiographic and IVUS ﬁndings
Coronary angiographic ﬁndings are summarized in Table 2.
There were no signiﬁcant differences in target vessel, American
College of Cardiology/American Heart Association lesion type, TIMI
ﬂow grade, and stent number and diameter, and stent overlap-
ping between both groups. However, stent length was signiﬁcantly
longer in the CKD group compared with the non-CKD group.Data are n (%), or mean± SD. CKD, chronic kidney disease; NSTEMI, non-ST segment
elevation myocardial infarction; STEMI, ST segment elevation myocardial infarc-
tion; PCI, percutaneous coronary intervention; hs-CRP, high-sensitivity C-reactive
protein; NT-pro-BNP, N-terminal pro-B type natriuretic peptide; LDL, low-density
lipoprotein; HDL, high-density lipoprotein.









Left main 2 (10.5%) 16 (7.0%)
Left anterior descending 10 (52.6%) 145 (63.3%)
Left circumﬂex 4 (21.1%) 27 (11.8%)
Right 3 (15.8%) 41 (17.9%)
ACC/AHA lesion type 0.121
B1 3 (15.8%) 64 (27.9%)
B2 16 (84.2%) 142 (62.0%)
C 0 (0.0%) 23 (10.0%)
TIMI ﬂow grade, n 0.909
0 1 (5.3%) 10 (4.4%)
1 0 (0.0%) 5 (2.2%)
2 3 (15.8%) 30 (13.1%)
3 15 (78.9%) 184 (80.3%)
Stent overlapping, n 4 (21.1%) 36 (15.7%) 0.544
Stent number 1.26±0.56 1.17±0.40 0.375
Stent diameter (mm) 3.34±0.34 3.39±0.46 0.668
Stent length (mm) 34.1±18.2 26.6±13.2 0.021
Inﬂation pressure (atm) 13.1±2.6 12.4±2.2 0.260
Data are n (%), or mean± SD. CKD, chronic kidney disease; ACC/AHA, American Col-
lege of Cardiology/American Heart Association; TIMI, Thrombolysis In Myocardial
Infarction.
Table 3
Baseline gray-scale and virtual histology intravascular ultrasound ﬁndings.
CKD (+)(n=19) CKD (−)(n=229) p-Value
Vessel volume (mm3) 375 ± 123 377 ± 204 0.966
Lumen volume (mm3) 153 ± 55 162 ± 87 0.728
Plaque volume (mm3) 221 ± 78 215 ± 124 0.862
%Plaque volume (%) 58.9 ± 5.9 56.1 ± 7.0 0.148
Absolute FT volume (mm3) 70.6 ± 28.9 75.6 ± 53.1 0.724
Absolute FF volume (mm3) 11.0 ± 5.0 13.6 ± 13.6 0.145
Absolute DC volume (mm3) 19.9 ± 15.5 15.2 ± 15.1 0.262
Absolute NC volume (mm3) 33.1 ± 23.2 25.6 ± 21.1 0.206
%FT volume (%) 53.2 ± 13.2 58.4 ± 10.5 0.086
%FF volume (%) 9.4 ± 5.6 10.2 ± 6.5 0.657










i%NC volume (%) 23.3 ± 10.1 19.9 ± 8.4 0.152
ata are mean± SD. CKD, chronic kidney disease; FT, ﬁbrotic; FF, ﬁbro-fatty;
C, dense calcium; NC, necrotic core.ollow-up medications and IVUS ﬁndings
Follow-up medications and gray-scale/VH-IVUS results are
ummarized in Table 4. Mean follow-up durations between DES
able 4







Follow-up duration (months) 12.0±4.1 11.4±5.6 0.519
Medications at follow-up
Aspirin 19 (100.0%) 224 (97.8%) 0.515
Clopidogrel 18 (94.7%) 219 (95.6%) 0.855
ACEI/ARB 17 (89.5%) 198 (86.5%) 0.710
Beta-blocker 15 (78.9%) 178 (77.7%) 0.902
Statin 15 (78.9%) 196 (85.6%) 0.435
Vessel volume (mm3) 392±134 383±214 0.136
Stent volume (mm3) 307±173 236±163 0.071
Lumen volume (mm3) 235±135 177±85 0.007
Neointima volume (mm3) 72±47 47±26 <0.001
%Volume obstruction (%) 23.7±7.9 21.5±8.4 0.275
%FT volume (%) 50.3±14.7 56.2±18.2 0.103
%FF volume (%) 6.7±3.6 11.8±5.2 0.043
%DC volume (%) 18.0±9.7 14.1±9.0 0.035
%NC volume (%) 25.0±11.4 17.9±10.2 0.012
ata are mean± SD. CKD, chronic kidney disease; FT, ﬁbrotic; FF, ﬁbro-fatty;
C, dense calcium; NC, necrotic core; ACEI/ARB, angiotensin-converting enzyme
nhibitor/angiotensin receptor blocker.iology 64 (2014) 98–104 101
implantation and follow-up IVUS study were 12.0±4.1 months
in the CKD group and 11.4±5.6 months in the non-CKD group.
There were no signiﬁcant differences in medications at follow-up
between the groups. At follow-up, neointima volume was signiﬁ-
cantly greater in the CKDgroup comparedwith the non-CKDgroup.
%Neointima NC and DC volumes were signiﬁcantly greater, in con-
trast %neointima FF volume was signiﬁcantly smaller in the CKD
group compared with the non-CKD group.
Correlations between CrCl and IVUS parameters
Therewereweak negative correlations between CrCl and neoin-
tima volume (r=−0.250, p<0.001, Fig. 2A) and between CrCl and
%volumeobstruction (r=−0.144,p=0.023), however, therewereno
signiﬁcant correlations between CrCl and %neointima NC volume
(r=−0.034, p=0.591, Fig. 2B) and between CrCl and %neointima DC
volume (r=−0.007, p=0.908). Instead, there were signiﬁcant pos-
itive correlations between neointima volume and %neointima NC
volume (r=0.329,p<0.001, Fig. 2C) andbetweenneointimavolume
and%neointimaDCvolume (r=0.248, p<0.001), andbetween%vol-
ume obstruction and %neointima NC volume (r=0.460, p<0.001,
Fig. 2D) and between %volume obstruction and %neointima DC
volume (r=0.302, p<0.001).
Independent predictors of follow-up %neointima NC volume ≥10%
Patients with follow-up %neointima NC volume ≥10% had
greater neointima volume (59±28mm3 vs. 42±26mm3,
p<0.001), greater %volume obstruction (25.8±7.5% vs. 18.5±7.7%,
p<0.001), and thereweremorediabetics (41.1%vs. 27.0%,p=0.019)
compared with those with follow-up %neointima NC volume <10%.
The independentpredictors of follow-up%neointimaNCvolume
≥10% are summarized in Table 5. The only independent predictor
of follow-up %neointima NC volume ≥10% was neointima volume
(odds ratio 1.025, 95% conﬁdence interval 1.013–1.036, p<0.001)
and diabetes mellitus approached signiﬁcance (odds ratio 1.748,
95% conﬁdence interval 0.980–3.117, p=0.058).
Discussion
The present study demonstrated that: (1) neointima volume
was signiﬁcantly greater in patientswith CKD comparedwith those
without CKD; (2) %neointima NC volume was signiﬁcantly greater
in patients with CKD compared with those without CKD; (3) there
was a negative correlation between CrCl and neointima volume,
however, there was no signiﬁcant correlation between CrCl and
%neointima NC volume; (4) there was signiﬁcant positive correla-
tion between neointima volume and %neointima NC volume; (5)
patients with follow-up %neointima NC volume ≥10% had greater
neointima volume, greater %volume obstruction, and were more
diabetics compared with those with follow-up %neointima NC vol-
ume <10%; and (6) neointima volume, but not renal function, was
the independent predictor of follow-up %neointima NC volume
≥10%.
Table 5
Independent predictors of follow-up %neointima necrotic core volume ≥10%.
Odds ratio 95% conﬁdence
interval
p-Value
Neointima volume (mm3) 1.025 1.013–1.036 <0.001
Diabetes mellitus 1.748 0.980–3.117 0.058
Acute coronary syndrome 0.714 0.367–1.390 0.322
Creatinine clearance (mL/min) 1.004 0.992–1.015 0.551
Follow-up duration (months) 1.008 0.960–1.059 0.745
























iig. 2. Correlations between creatinine clearance and neointima volume (A), betw
olume and %neointima necrotic core volume (C), and between %volume obstructio
Patientswith decreased renal function havemore future risks of
eath, myocardial infarction, repeat revascularization, and bleed-
ng complications after PCI comparedwith thosewith normal renal
unction [1–11]. Several studieshavedemonstrated that renal func-
ion is associated with in-stent restenosis by neointimal growth
fter PCI for DES restenosis [19] as well as after DES implanta-
ion for de novo lesions of native coronary artery disease [20–26].
n the present study, renal function was associated with greater
eointimal growth at one-year after DES implantation.
Several studies have reported that neoatherosclerosis devel-
ped more frequently in DES-treated lesions compared with
are-metal stent (BMS)-treated lesions [27–30]. Nakazawa et al.
28] reported that the incidence of neoatherosclerosis was
igniﬁcantly greater in DES (31%) than BMS (16%) lesions.
eoatherosclerosis attributed to DES may be more related to
ncomplete endothelialization as opposed to shear stress for BMS.
Yonetsu et al. [29] reported that CKD is one of the predictors of
eoatherosclerosis. However, in the present study, renal function
as not associated with the development of in-stent NC and DC at
ne-year follow-up after DES implantation, instead, the amount
f follow-up neoimtima was the independent predictor of large
mount of in-stent neointima NC. Therefore, the amount of neoin-
ima, but not renal function, is an important predictor of in-stent
eoatherosclerosis in patients at short-term follow-up after DES
mplantation. This result suggests that we should try to reduce thereatinine clearance and %neointima necrotic core volume (B), between neointima
%neointima necrotic core volume (D).
factors causing neointimal hyperplasia such as stent underexpan-
sion or geographic miss at the time of DES implantation and to
reduce neointimal formation using intensive medical therapy and
vigorous lifestyle modiﬁcation in patients with renal dysfunction
to reduce the development of neoathersclerosis.
Previous studies reported that neoatherosclerosis occurs ear-
lier in DES-treated lesions compared with BMS-treated lesions
[27–30]. Time since stent implantation (stent age) is one of the
important factors for the development of in-stent neoatheroscle-
rosis. Nakazawa et al. [28] reported that the median stent
duration with neoatherosclerosis was shorter in DES than BMS
[DES, 420 (361–683) days vs. BMS, 2160 (1800–2880) days] and
longer implant durations were the independent determinants of
neoatherosclerosis. The earlier development of neoatherosclero-
sis in DES compared to BMS is probably related to drug effects,
which are also responsible for incomplete endothelialization [28].
Yonetsu et al. [29] reported that stent age ≥48 months was a
predictor of neoatherosclerosis in patients with mean neointimal
thickness >100musing optical coherence tomography. Kang et al.
[30] reported that DES restenosis lesions that have been implanted
for longer periods and develop late in-stent restenosis have in-
stent tissue composition that includes NC and DC suggestive of
in-stent neoatherosclerosis in patients with angiographic in-stent
restenosis and intimal hyperplasia >50% of the stent area. They

































































sirolimus-eluting stent restenosis. Coron Artery Dis 2012;23:528–32.Y.J. Hong et al. / Journal o
reater%NCand%DCatmaximal%intimalhyperplasia andmaximal
NC sites, especially in stents that had been implanted for longer
eriods. In the present study, time interval from DES implantation
o follow-up was not associated with in-stent neoatherosclerosis.
n the present study, follow-up duration from DES implantation
o follow-up VH-IVUS examination was about one year, and we
ncluded all patientswithmeasurable neointima aswell as patients
ith large amount of neointima. In the present study, the amount
f neointima rather than stent age was an important predictor
f neoatherosclerosis. This result suggests that stent age is an
mportant factor of in-stent neoatherosclerosis in patientswhohad
onger periods of DES implantation especially in patientswith large
mount of intimal hyperplasia.
tudy limitations
First, the analyses were retrospective and are subject to lim-
tations inherent in this type of clinical investigation. Second,
ray-scale and VH-IVUS imaging were performed at the discre-
ion of the individual operators, leading to potential selection
ias. Third, although VH-IVUS can evaluate the components of
therosclerotic plaques with high accuracy compared to histol-
gy [31], no studies have reported the direct comparison data for
eointimal tissue between VH-IVUS and histopathology. However,
merging evidence suggests that in-stent tissue development is
imilar to de novo atherosclerosis in native arteries. Fourth, we
ould not determine the cause and duration of decreased renal
unction and did not have information regarding microalbumin-
ria orproteinuria. Fifth,wedeﬁneddecreased renal functionbased
n estimated CrCl rather than direct measurements of glomerular
ltration rate. Sixth, there were very few patients with advanced
idney disease; therefore, the results of this study should not be
xtrapolated to advance stages of CKD. Seventh, heavily calciﬁed
laquesmay induceanartifact regarding the codiﬁcationof plaques
y VH-IVUS resulting in an increase in NC content. This remains a
otential limitation of the present VH study. Eighth, we included
our types of DESs in the present study. The neointimal tissue char-
cteristics might be different among the four DES types. Ninth,
nalyzing neointimal tissue characteristics of non-culprit, non-
arget sites might be better to know about the natural history of
therosclerosis. However, we have few VH-IVUS data after sten-
ing for non-culprit, non-target lesions. Therefore, we analyzed the
eointimal tissue components at the target lesion. Tenth, we could
ot demonstrate the relation between neointimal composition and
ong-term clinical events.
onclusions
Renal function was related to the neointimal growth, but it was
ot associatedwith neointimaNC formation, instead the amount of
eointimawas associatedwithmore neoatherosclerosis in patients
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